FleurirABX

FleurirABX is a privately held, pre-clinical stage biotechnology company focused on developing synergistic combination antibiotics to combat the global crisis of antimicrobial resistance. The company's lead program, FTS, is a patented combination of two established small-molecule antibiotics, fosfomycin and trimethoprim-sulfamethoxazole (co-trimoxazole). By targeting convergent bacterial metabolic pathways, FTS achieves enhanced potency and a broader spectrum of activity against both Gram-positive and Gram-negative pathogens, including drug-resistant strains. FleurirABX leverages the well-documented safety profiles of these existing drugs to potentially streamline the regulatory approval process. The company aims to provide effective, affordable treatments for indications such as urinary tract infections, acute bacterial skin and skin structure infections, and respiratory tract infections.